Literature DB >> 24854157

Plasma profile of pro-inflammatory cytokines and chemokines in cocaine users under outpatient treatment: influence of cocaine symptom severity and psychiatric co-morbidity.

Pedro Araos1, María Pedraz1, Antonia Serrano1, Miguel Lucena1, Vicente Barrios2, Nuria García-Marchena1, Rafael Campos-Cloute3, Juan J Ruiz4, Pablo Romero1, Juan Suárez1, Elena Baixeras1, Rafael de la Torre5,6, Jorge Montesinos7, Consuelo Guerri7, Marta Rodríguez-Arias8, José Miñarro8, Roser Martínez-Riera5,9,10, Marta Torrens5,9,10, Julie A Chowen2, Jesús Argente2, Barbara J Mason11, Francisco J Pavón1, Fernando Rodríguez de Fonseca1.   

Abstract

The treatment for cocaine use constitutes a clinical challenge because of the lack of appropriate therapies and the high rate of relapse. Recent evidence indicates that the immune system might be involved in the pathogenesis of cocaine addiction and its co-morbid psychiatric disorders. This work examined the plasma pro-inflammatory cytokine and chemokine profile in abstinent cocaine users (n = 82) who sought outpatient cocaine treatment and age/sex/body mass-matched controls (n = 65). Participants were assessed with the diagnostic interview Psychiatric Research Interview for Substance and Mental Diseases according to the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR). Tumor necrosis factor-alpha, chemokine (C-C motif) ligand 2/monocyte chemotactic protein-1 and chemokine (C-X-C motif) ligand 12 (CXCL12)/stromal cell-derived factor-1 (SDF-1) were decreased in cocaine users, although all cytokines were identified as predictors of a lifetime pathological use of cocaine. Interleukin-1 beta (IL-1β), chemokine (C-X3-C motif) ligand 1 (CX3CL1)/fractalkine and CXCL12/SDF-1 positively correlated with the cocaine symptom severity when using the DSM-IV-TR criteria for cocaine abuse/dependence. These cytokines allowed the categorization of the outpatients into subgroups according to severity, identifying a subgroup of severe cocaine users (9-11 criteria) with increased prevalence of co-morbid psychiatric disorders [mood (54%), anxiety (32%), psychotic (30%) and personality (60%) disorders]. IL-1β was observed to be increased in users with such psychiatric disorders relative to those users with no diagnosis. In addition to these clinical data, studies in mice demonstrated that plasma IL-1β, CX3CL1 and CXCL12 were also affected after acute and chronic cocaine administration, providing a preclinical model for further research. In conclusion, cocaine exposure modifies the circulating levels of pro-inflammatory mediators. Plasma cytokine/chemokine monitoring could improve the stratification of cocaine consumers seeking treatment and thus facilitate the application of appropriate interventions, including management of heightened risk of psychiatric co-morbidity. Further research is necessary to elucidate the role of the immune system in the etiology of cocaine addiction.
© 2014 Society for the Study of Addiction.

Entities:  

Keywords:  Binge; PRISM; chronic intoxication; cocaine; mice; psychiatric co-morbidity; substance use disorders

Mesh:

Substances:

Year:  2014        PMID: 24854157     DOI: 10.1111/adb.12156

Source DB:  PubMed          Journal:  Addict Biol        ISSN: 1355-6215            Impact factor:   4.280


  39 in total

1.  Chemokine CCR5 and cocaine interactions in the brain: Cocaine enhances mesolimbic CCR5 mRNA levels and produces place preference and locomotor activation that are reduced by a CCR5 antagonist.

Authors:  Sunil U Nayak; Stephanie Cicalese; Chris Tallarida; Chicora F Oliver; Scott M Rawls
Journal:  Brain Behav Immun       Date:  2019-09-23       Impact factor: 7.217

2.  Parallel Effects of Methamphetamine on Anxiety and CCL3 in Humans and a Genetic Mouse Model of High Methamphetamine Intake.

Authors:  Marilyn Huckans; Clare J Wilhelm; Tamara J Phillips; Elaine T Huang; Rebekah Hudson; Jennifer M Loftis
Journal:  Neuropsychobiology       Date:  2018-01-18       Impact factor: 2.328

Review 3.  Imaging Biomarkers of the Neuroimmune System among Substance Use Disorders: A Systematic Review.

Authors:  Eric A Woodcock; Ansel T Hillmer; Graeme F Mason; Kelly P Cosgrove
Journal:  Mol Neuropsychiatry       Date:  2019-05-09

4.  Innate immune signaling in the ventral tegmental area contributes to drug-primed reinstatement of cocaine seeking.

Authors:  Kyle T Brown; Sophia C Levis; Casey E O'Neill; Alexis L Northcutt; Timothy J Fabisiak; Linda R Watkins; Ryan K Bachtell
Journal:  Brain Behav Immun       Date:  2017-08-13       Impact factor: 7.217

Review 5.  Neuroimmune mechanisms of psychostimulant and opioid use disorders.

Authors:  Rebecca S Hofford; Scott J Russo; Drew D Kiraly
Journal:  Eur J Neurosci       Date:  2018-09-26       Impact factor: 3.386

6.  Chemokines and 'bath salts': CXCR4 receptor antagonist reduces rewarding and locomotor-stimulant effects of the designer cathinone MDPV in rats.

Authors:  Chicora F Oliver; Steven J Simmons; Sunil U Nayak; Garry R Smith; Allen B Reitz; Scott M Rawls
Journal:  Drug Alcohol Depend       Date:  2018-03-10       Impact factor: 4.492

7.  Chemokines and cocaine: CXCR4 receptor antagonist AMD3100 attenuates cocaine place preference and locomotor stimulation in rats.

Authors:  Jae Kim; Krista L Connelly; Ellen M Unterwald; Scott M Rawls
Journal:  Brain Behav Immun       Date:  2016-08-26       Impact factor: 7.217

Review 8.  DARK Classics in Chemical Neuroscience: Cathinone-Derived Psychostimulants.

Authors:  Steven J Simmons; Jonna M Leyrer-Jackson; Chicora F Oliver; Callum Hicks; John W Muschamp; Scott M Rawls; M Foster Olive
Journal:  ACS Chem Neurosci       Date:  2018-05-11       Impact factor: 4.418

Review 9.  Chemokines, cytokines and substance use disorders.

Authors:  Olivia C Ahearn; Mia N Watson; Scott M Rawls
Journal:  Drug Alcohol Depend       Date:  2021-01-08       Impact factor: 4.492

Review 10.  A "Drug-Dependent" Immune System Can Compromise Protection against Infection: The Relationships between Psychostimulants and HIV.

Authors:  María Amparo Assis; Pedro Gabriel Carranza; Emilio Ambrosio
Journal:  Viruses       Date:  2021-04-21       Impact factor: 5.048

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.